Vir Biotechnology, Inc. · NASDAQ:VIR

Vir Biotechnology — Technical Presentation (November 2026)

23 slides from Vir Biotechnology's technical presentation, Nov 9, 2026

  1. Slide 1: ECLIPSE 1 Pivotal Phase 3 Topline Results and SOLSTICE Phase 2 Finite Treatment Data

    ECLIPSE 1 Pivotal Phase 3 Topline Results and SOLSTICE Phase 2 Finite Treatment Data November 9, 2026 2026 Vir Biotechnology, Inc.

  2. Slide 2: Legal Disclaimer

    Legal Disclaimer Forward-looking Statements Statements in this presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding: the therapeutic and commercial potential of Vir Biotechnology's CH

  3. Slide 3: Elebsiran and tobevibart: Best-in-disease data for chronic hepatitis delta

    Elebsiran and tobevibart: Best-in-disease data supporting a potentially transformative treatment for chronic hepatitis delta ECLIPSE Phase 3: Met Primary and Key Secondary Endpoints SOLSTICE Phase 2: Curative Potential 79% 100% 10/10 Undetectable virus at 48 weeks Undetectable virus at 96 Sustained

  4. Slide 4: Chronic hepatitis delta significantly underserved with high mortality and morbidity

    Chronic hepatitis delta, a devastating liver disease, significantly underserved with high mortality and morbidity >50% 5 Years 3x LIVER-RELATED DEATH IN AVERAGE PROGRESSION TO RISK OF LIVER CANCER (HCC) 10 YEARS1 CIRRHOSIS AND LIVER FAILURE2 VS. HBV ALONE3 ~61K ~113K ~7M Active viremic patients5 in

  5. Slide 5: Positive Phase 3 ECLIPSE 1 Topline Data

    Positive Phase 3 ECLIPSE 1 Topline Data 2026 Vir Biotechnology, Inc. 5

  6. Slide 6: Mechanism of action and ECLIPSE 1 study design

    Mechanism of action and ECLIPSE 1 study design Two-Pronged Approach: Elebsiran and Tobevibart Elebsiran (siRNA) Degrades HBV RNA Reduces HBsAg production Q4W Monthly subcutaneous dosing Elebsiran 200 mg and tobevibart 300 mg Tobevibart (mAb) Flexible administration setting Neutralizes HDV and HBV vi

  7. Slide 7: ECLIPSE 1 baseline characteristics

    ECLIPSE 1 baseline characteristics: Broad and diverse CHD patient population, including patients with advanced disease Elebsiran and Tobevibart Delayed Treatment Q4W N = 41 N = 83 Cirrhotic patients1, n (%) 46 (55.4) 23 (56.1) Liver stiffness, kPa 13.3 ± 5.5 13.7 ± 5.6 ALT, U/L 94.0 ± 42.3 112.6 ± 6

  8. Slide 8: ECLIPSE 1 met all study endpoints

    ECLIPSE 1 met all study endpoints: Elebsiran and tobevibart demonstrates potential for best-in-disease efficacy Elebsiran and Tobevibart Q4W Delayed Treatment at Week 48 (N = 83) at Week 12 (N = 41) Primary endpoint: Undetectable virus (HDV RNA TND) + ALT normalization, (%) 44.1 0.0 p-value <0.0001

  9. Slide 9: Rapid and deepening virologic response and ALT normalization through Week 48

    Rapid and deepening virologic response and ALT normalization increasing through Week 48 HDV RNA ALT normalization 100% 99% 100% 100 100 96% 80 31% 79% 35% % of participants Week 4 36% 80 73% 60% % of participants 60 80% 16% 25% 24% 57% Elebsiran and Tobevibart Q4W 60 HDV RNA TND or HDV RNA ≥2 log10

  10. Slide 10: Viral responses similar in noncirrhotic and compensated cirrhotic patients at Week 48

    Viral responses and ALT normalization were similar in noncirrhotic and compensated cirrhotic patients at Week 48 Elebsiran and Tobevibart Q4W N = 83 Noncirrhotic Compensated Cirrhotic N = 37 N = 46 Undetectable virus (HDV RNA TND) 45.9 43.5 + ALT normalization, (%) Undetectable virus (HDV RNA TND),

  11. Slide 11: HBsAg suppression deepens over time

    Hepatitis B surface antigen is a critical component of the delta virus life cycle: Suppression of HBsAg deepens over time Changes in HBsAg with elebsiran and tobevibart 100 HBsAg Categories 80 20% (IU/mL) % of participants <0.05 (LOD of the assay) 60 0.05 to <10 10 to <100 40 70% 87% 89% ≥100 Missin

  12. Slide 12: Combination regimen is well tolerated with a favorable safety profile

    Combination regimen is well tolerated with a favorable safety profile Elebsiran and Tobevibart Delayed treatment Safety or tolerability measure, n (%)1 Q4W2 through Week 48, through Week 12, N = 83 N = 41 Any AE 69 (83.1)3 13 (31.7) Any treatment-related TEAE 59 (71.1) 0 • Majority of adverse events

  13. Slide 13: Updated Phase 2 SOLSTICE Week 96 Data

    Updated Phase 2 SOLSTICE Week 96 Data 2026 Vir Biotechnology, Inc. 13

  14. Slide 14: Phase 2 SOLSTICE study design

    Phase 2 SOLSTICE study design Key eligibility: HDV RNA >500 IU/mL; ALT >ULN and <5×ULN; on NRTI; non-cirrhotic1 or cirrhotic (CPT-A)2 Primary Endpoint • HDV RNA TND + ALT N=32 Elebsiran 200 mg and tobevibart 300 mg SC Q4W normalization at Week 24 • TEAEs and serious TEAEs N=33 Tobevibart 300 mg SC Q

  15. Slide 15: High rates of undetectable virus and ALT normalization through Week 96

    High rates of undetectable virus deepen over time and increasing rates of ALT normalization through Week 96 HDV RNA TND ALT 97% LOCF Analysis 100 100 3% achieving HDV RNA TND 84% MEF Analysis 9% 16% 80 25% ALT Category % of participants 88% 69% 80 16% 9% 78% % participants 9% <ULN 60 66% 16% 1 to 1.

  16. Slide 16: Reduced liver stiffness consistent with potential reduction in fibrosis

    Reduced liver stiffness is consistent with a potential reduction in fibrosis 5 Individual Participant (N=271) Liver Stiffness (kPa) 0 Change in -5 -10 -15 -20 Noncirrhotic Compensated cirrhotic Among patients with paired liver stiffness measurements (LSM), 89% showed improved or stable LSM results a

  17. Slide 17: SOLSTICE Finite Treatment Exploratory Analysis

    SOLSTICE Finite Treatment Exploratory Analysis 2026 Vir Biotechnology, Inc. 17

  18. Slide 18: SOLSTICE finite treatment: Exploratory analysis study design

    SOLSTICE finite treatment: Exploratory analysis study design Finite Treatment Eligibility Exploratory Endpoint 96+ WEEKS Optional Treatment Discontinuation Patients may discontinue treatment once eligibility criteria are met HDV RNA TND resulting in variable treatment durations while on combination

  19. Slide 19: Sustained viral response after stopping treatment suggests curative potential

    Sustained viral response (SVR) after stopping treatment suggests curative potential in hepatitis delta1 TND Pt. 12 Pt. 23 Pt. 3 Pt. 4 Pt. 53 Pt. 63 Pt. 73 Pt. 83 Pt. 93 Pt. 103 TND duration on 100 wks 108 wks 96 wks 96 wks 96 wks 96 wks 96 wks 100 wks 96 wks 104 wks treatment4 SVR follow 48 wks 44 w

  20. Slide 20: Next Steps

    Next Steps 2026 Vir Biotechnology, Inc. 20

  21. Slide 21: ECLIPSE 1 positive topline data, ECLIPSE 2 and 3 topline data in Q1 2027

    ECLIPSE 1 positive topline data, ECLIPSE 2 and 3 topline data in Q1 2027 FDA breakthrough FDA Fast Track EMA PRIME EMA Orphan Drug designation designation designation designation ECLIPSE 1 ECLIPSE 2 ECLIPSE 3 PRIMARY ENDPOINT AT PRIMARY ENDPOINT AT PRIMARY ENDPOINT AT Week 48 Week 24 Week 48 Primary

  22. Slide 22: Elebsiran and tobevibart: Best-in-disease data for chronic hepatitis delta

    Elebsiran and tobevibart: Best-in-disease data supporting a potentially transformative treatment for chronic hepatitis delta ECLIPSE Phase 3: Met Primary and Key Secondary Endpoints SOLSTICE Phase 2: Curative Potential 79% 100% 10/10 Undetectable virus at 48 weeks Undetectable virus at 96 Sustained

  23. Slide 23: Patients are waiting

    PATIENTS ARE WAITING 2026 Vir Biotechnology, Inc. 2026 Vir Biotechnology, Inc. 23

Vir Biotechnology — Technical Presentation (November 2026) on 6ix